HC Wainwright Has Positive Outlook for PLX Q1 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at HC Wainwright increased their Q1 2025 earnings estimates for Protalix BioTherapeutics in a research report issued on Monday, April 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.08 for the quarter, up from their previous forecast of $0.03. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.45 EPS.

Separately, StockNews.com cut Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th.

Protalix BioTherapeutics Stock Performance

NYSE:PLX opened at $3.00 on Thursday. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $3.10. The company has a 50 day moving average price of $2.51 and a 200 day moving average price of $2.09. The stock has a market capitalization of $234.10 million, a P/E ratio of -23.08 and a beta of 0.46.

Institutional Trading of Protalix BioTherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in shares of Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock valued at $2,102,000 after purchasing an additional 162,100 shares during the period. Northern Trust Corp boosted its position in Protalix BioTherapeutics by 1,299.4% in the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company’s stock valued at $1,376,000 after buying an additional 679,451 shares during the period. Millennium Management LLC grew its stake in shares of Protalix BioTherapeutics by 3.8% in the fourth quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock worth $729,000 after acquiring an additional 14,164 shares in the last quarter. Stratos Wealth Partners LTD. grew its stake in shares of Protalix BioTherapeutics by 28.3% in the first quarter. Stratos Wealth Partners LTD. now owns 346,400 shares of the company’s stock worth $887,000 after acquiring an additional 76,400 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of Protalix BioTherapeutics by 147.2% during the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock worth $214,000 after acquiring an additional 67,664 shares during the period. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.